ArticleLeukemia2013
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
M A Hurchla et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this papertrialcites it